|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | The University of Texas Health Science Center, Houston |
|---|---|
| Collaborator: |
The Institute of Rehabilitation and Research (TIRR) |
| Information provided by (Responsible Party): | Georgene Hergenroeder, The University of Texas Health Science Center, Houston |
| ClinicalTrials.gov Identifier: | NCT00913471 |
Purpose
The investigators propose to compare plasma protein profiles for SCI patients with/without chronic neuropathic pain in order identify biomarker(s) that are associated with this medical condition. Secondly, the investigators propose to identify a temporal relationship to initial SCI at which these biomarkers manifest.
Our working hypothesis is that sustained alterations in specific inflammatory molecules are associated with chronic neuropathic pain following SCI, and that their plasma levels can serve as biomarkers to identify patients at risk for the development of neuropathic pain.
Additionally the investigators are collecting skin tissue biopsy samples from patients following acute and chronic spinal cord injury to create vector-free human iPS cells from fibroblasts by direct delivery of reprogramming proteins.
| Condition | Intervention |
|---|---|
|
Traumatic Spinal Cord Injury Neuropathic Pain |
Other: blood samples |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Biomarkers for Pain in Spinal Cord Injury (SCI) Patients |
blood samples (120 subjects) and skin tissue biopsy (20 subjects)
| Estimated Enrollment: | 120 |
| Study Start Date: | June 2009 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| Acute-Longitudinal SCI |
Other: blood samples
Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample. Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample. Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy. |
| Chronic SCI |
Other: blood samples
Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample. Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample. Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy. |
| Healthy volunteers |
Other: blood samples
Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample. Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample. Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy. |
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Acute and Chronic traumatic spinal cord injury patients and healthy volunteers
A. Chronic Patients
Inclusion:
1. Two or more years post traumatic SCI with deficit
Exclusion:
B. Longitudinal, Prospective Cohort Patients:
Inclusion:
1. Initial traumatic SCI with deficit
Exclusion:
Same as listed above C. Healthy Volunteers Healthy volunteers include gender, age and race matched volunteers able to provide informed consent who have,
Contacts and Locations| Contact: Georgene W Hergenroeder, MHA, RN | Georgene.W.Hergenroeder@uth.tmc.edu |
| United States, Texas | |
| Memorial Hermann Hospital | Recruiting |
| Houston, Texas, United States, 77030 | |
| Principal Investigator: | Georgene Hergenroeder, MHA, RN | UTHSC-Houston |
More Information
| Responsible Party: | Georgene Hergenroeder, Assistant Professor, Neurosurgery, The University of Texas Health Science Center, Houston |
| ClinicalTrials.gov Identifier: | NCT00913471 History of Changes |
| Other Study ID Numbers: | HSC-MS-07-0452 |
| Study First Received: | June 2, 2009 |
| Last Updated: | November 17, 2011 |
| Health Authority: | United States: Institutional Review Board |
|
Spinal cord injury SCI Neuropathic pain Pain |
|
Neuralgia Spinal Cord Injuries Pain Neurologic Manifestations Nervous System Diseases Peripheral Nervous System Diseases |
Neuromuscular Diseases Signs and Symptoms Spinal Cord Diseases Central Nervous System Diseases Trauma, Nervous System Wounds and Injuries |